TSXV: DVA
TORONTO, April 24, 2018 /CNW/ - Delivra Corp. ("Delivra",
or "the Company") today announced the ability to treat pain
directly with a topical version of Advil™ (ibuprofen). Testing for
effects on joint pain and inflammation, topical Delivra-ibuprofen
formulation offers long-term pain and swelling reduction compared
to oral ibuprofen.
In pre-clinical testing, undertaken by an independent
third-party research organization, the Delivra-ibuprofen
formulation provided sustained pain reduction. In the study,
Delivra-ibuprofen was tested in an acute canine model of arthritis
where the formulation performed equally or better for swelling and
pain reduction compared its oral equivalent and test controls. This
exemplifies Delivra's technology, with its multi-layer liposomal
system, is capable of gradually releasing the active ingredient to
the area of need. This transdermal "slow release" is a valuable and
highly advantageous characteristic of the topical Delivra-ibuprofen
cream and may offer significant advantages over oral medication,
with better localization of the drug at the site of need, yielding
quicker and longer lasting relief.
"This impressive pre-clinical data further validates Delivra's
platform technology by outperforming both oral delivery and a
leading transdermal base, and offering patients an effective, safe
and convenient cream for pain. With a robust pharmaceutical
pipeline of high-value innovative products, Delivra-ibuprofen
formulation promises a unique commercialization opportunity. As
such, we, will continue to pursue out-licensing opportunities for
major global markets to unlock the value of our portfolio," said
Dr. Joseph Gabriele, CEO of
Delivra.
Delivra's research and development includes pharmaceutical
formulations, compounding, stability testing, and measurement of
localized penetration and delivery of drugs including ibuprofen.
The Company is advancing this Delivra-ibuprofen formulation as the
patent-pending technology, entitled "Transdermal formulations for
delivery of propionic and acetic acid NSAIDs and their use in the
treatment of NSAID-responsive diseases and conditions".
Delivra has filed a provisional U.S. patent to protect its
unique formulation and it is currently available by prescription
across Canada through the compound
pharmacy services of NKS Health Ltd.
ABOUT DELIVRA CORP.
Delivra Corp. is a specialty biotechnology company having a
proprietary transdermal delivery system platform that can shuttle
pharmaceutical and natural molecules through the skin, in a
targeted manner. Delivra manufactures and sells a growing line of
natural topical creams with the proprietary transdermal delivery
system platform under the LivRelief™ brand, for conditions such as
joint and muscle pain, nerve pain, varicose veins, wound healing,
and under the LivSport™ brand for sports performance. LivRelief™
products are available in pharmacies, grocery chains, and
independent health food stores across Canada, including, but not limited to,
Shoppers Drug Mart, Walmart, Loblaw, Rexall, Pharmasave, London
Drugs, and on-line at www.livrelief.com. In parallel with its
consumer products business, Delivra also has a mandate to license
its patent-pending, proprietary transdermal delivery technology
platform to pharmaceutical companies globally, for the repurposing
of pharmaceutical molecules transdermally to treat a broad range of
conditions, along with licensing its over-the-counter products
globally. Delivra is headquartered in Hamilton, Ontario and has a research and
development laboratory in Charlottetown, PEI.
Further information on Delivra can be found at
www.delivracorp.com and www.livrelief.com.
Cautionary Note Regarding Forward-Looking Statements
This news release includes certain information and statements
about management's view of future events, expectations, plans and
prospects that constitute "forward-looking statements", which are
not comprised of historical facts. Forward-looking statements may
be identified by such terms as "believes", "anticipates",
"intends", "expects", "estimates", "may", "could", "would", "will",
or "plan", and similar expressions. Specifically, forward-looking
statements in this news release include, without limitation,
statements regarding: the Company's revenues and financial
performance; the Company's drug research and development plans; the
timing of operations; and estimates of market conditions. These
statements involve known and unknown risks, uncertainties, and
other factors that may cause actual results or events, performance,
or achievements of Delivra to differ materially from those
anticipated or implied in such forward-looking statements. The
Company believes that the expectations reflected in these
forward-looking statements are reasonable, but there can be no
assurance that actual results will meet management's expectations.
In formulating the forward-looking statements contained herein,
management has assumed that business and economic conditions
affecting Delivra will continue substantially in the ordinary
course and will be favourable to Delivra; that the Company will
continue to complete orders with existing customers and control
product pricing and expenses that clinical testing results will
justify commercialization of the Company's drug candidates; that
Delivra will be able to obtain all requisite regulatory approvals
to commercialize its drug candidates, that such approvals will be
received on a timely basis, and that Delivra will be able to find
suitable partners for development and commercialization of its
products and intellectual property on favourable terms. Although
these assumptions were considered reasonable by management at the
time of preparation, they may prove to be incorrect. Factors that
may cause actual results to differ materially from those
anticipated by these forward-looking statements include: the
ability of the Company to maintain existing product sales with
current customers at existing product pricing and expenses;
uncertainties associated with obtaining regulatory approval to
perform clinical trials and market products; the need to establish
additional corporate collaborations, distribution or licensing
arrangements; the ability of the Company to generate sales and
profits; the Company's ability to raise additional capital if and
when necessary; intellectual property disputes; increased
competition from pharmaceutical and biotechnology companies;
changes in equity markets, inflation, and changes in exchange
rates; and other factors as described in detail in Delivra's public
filings, all of which may be viewed on SEDAR (www.sedar.com). Given
these risks and uncertainties, readers are cautioned not to place
undue reliance on such forward-looking statements and information,
which are qualified in their entirety by this cautionary statement.
Except as required by law, Delivra disclaims any intention and
assumes no obligation to update or revise any forward-looking
statements to reflect actual results, whether as a result of new
information, future events, changes in assumptions, changes in
factors affecting such forward-looking statements or otherwise.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
SOURCE Delivra Corp
